Christopher Yasiejko
Correspondents at Bloomberg News
Patents/®️/©️, IP@BLaw. Past: @business, @nytimes, @delawareonline. Bylines: @PhillyInquirer, @PhillyDailyNews, @CJR, +. Views=mine. RT≠endorsement. Tips? DM.
Articles
-
1 week ago |
news.bloomberglaw.com | Christopher Yasiejko
A federal judge canceled an upcoming jury trial after voiding two patents covering ways to deliver medicine to bones that Spinal Generations LLC alleged Johnson & Johnson’s DePuy Synthes Inc. unit infringed. Chief Judge Colm F. Connolly granted DePuy’s request for summary judgment that US Patent Nos. 8,808,337 and 7,575,572 are invalid, according to an opinion issued April 11 in the US District Court for the District of Delaware. He nixed the trial that had been set to begin April 28.
-
1 week ago |
news.bloomberglaw.com | Christopher Yasiejko
agreed to end a patent-infringement lawsuit that sought to block a copy of its ProAir HFA inhaler proposed by Deva Holding AS, one month after the Federal Circuit ordered Teva to de-list certain patents from the FDA’s Orange Book. The deal leaves the door open for either side to renew its allegations, according to a proposed consent dismissal order filed Thursday in the US District Court for the District of New Jersey. Neither Teva nor Deva immediately responded to requests for comments.
-
1 week ago |
news.bloombergtax.com | Christopher Yasiejko
Teva Pharmaceutical Industries Ltd. agreed to end a patent-infringement lawsuit that sought to block a copy of its ProAir HFA inhaler proposed by Deva Holding AS, one month after the Federal Circuit ordered Teva to remove certain patents from an FDA registry. The deal leaves the door open for either side to renew its allegations, according to a proposed consent dismissal order filed Thursday in the US District Court for the District of New Jersey. Magistrate Judge Michael A.
-
2 weeks ago |
news.bloombergtax.com | Christopher Yasiejko
Bausch & Lomb Inc. and SBH Holdings LLC agreed to end a patent-infringement lawsuit over rival eye-health supplements less than two weeks before a scheduled jury trial in Delaware federal court. The deal blocks both sides from renewing allegations, according to a stipulation of dismissal approved Thursday by Judge Gregory B. Williams in the US District Court for the District of Delaware.
-
2 weeks ago |
news.bloomberglaw.com | Christopher Yasiejko
Novo Nordisk A/S and Eli Lilly & Co. are using dense clusters of patents to extend monopolies on blockbuster diabetes and weight-loss drugs including Ozempic, Wegovy, and Mounjaro, fueling high prices and health inequities, according to an advocacy group report.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 688
- Tweets
- 2K
- DMs Open
- Yes
Import 300K bottles of generic Entresto in August & 2,200 kg of the blockbuster heart-failure drug’s active ingredient in December, and what do you get? A @Novartis suit seeking damages for @MSNLabs' alleged infringement of a recently revived patent. https://t.co/EaQPvBdVPw
Thanks for the shout-out, @cmorten2! And thanks to Chris Morten (of @ColumbiaLaw), @PrEP4AllNow, @TAGTeam_Tweets & @reshmagar, each of whom shared time and energy discussing the basis for their perspectives on @HHSGov's settlement last week w/ @GileadSciences on PrEP drugs.
@yasiejko (@bloomberglaw) has a new follow-up story on the landmark settlement in US v. Gilead—the billion-dollar patent fight over HIV PrEP. I'm quoted, along with Jeremiah Johnson (@PrEP4AllNow), Mark Harrington (@TAGTeam_Tweets) and @reshmagar. 1/ https://t.co/OH2KZjPohR
From the SIGN HERE; NO, REALLY Dept.🖋️: @AstellasUS can’t enforce a patent-infringement settlement with @MSNLabs over a generic version of the overactive-bladder drug Myrbetriq because the deal was never signed, a federal judge ruled. https://t.co/EQ6L9PvNg0